Physician profile
Reshma M Khan
NPI 1851602221
$160,649.81
in general payments reported to CMS, 2019-2025
28 companies · $2,631 in 2025
The $2,631 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $45K · 2021: $43K · 2022: $19K · 2023: $14K · 2024: $2,021 · 2025: $2,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $4,900 · Food and Beverage: $3,034 · Travel and Lodging: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,075.00 |
| Consulting Fee | $4,900.00 |
| Food and Beverage | $3,033.57 |
| Travel and Lodging | $789.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84,332.93 | 2019-2024 | Enbrel, Amjevita, Prolia |
| Glaxosmithkline, LLC. | $50,848.63 | 2019-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $16,242.59 | 2019-2025 | Tremfya, Stelara, Remicade |
| Horizon Therapeutics Plc | $3,095.88 | 2019-2022 | |
| Progentec Diagnostics, INC. | $2,400.00 | 2025 | |
| Abbvie INC. | $882.08 | 2019-2025 | |
| Ucb, INC. | $681.72 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $438.01 | 2019-2025 | Taltz, Zepbound, Mounjaro |
| Radius Health, INC. | $325.62 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $213.88 | 2019-2021 | |
| Pfizer INC. | $179.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $152.30 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $110.92 | 2020-2024 | Acthar |
| Janssen Pharmaceuticals, INC | $98.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $95.55 | 2020-2024 | Strensiq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $92.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.76 | 2019-2024 | |
| Genentech USA, INC. | $71.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.78 | 2020 | |
| Bioventus LLC | $40.47 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $40.47 | 2019 | |
| Genzyme Corporation | $38.60 | 2019-2023 | |
| Sobi, INC | $31.20 | 2019 | |
| Merck Sharp & Dohme LLC | $27.21 | 2019-2020 | |
| Fidia Pharma USA INC. | $23.47 | 2025 | Triluron, Hymovis |
| Pacira Therapeutics, INC. | $21.04 | 2020 | |
| Ani Pharmaceuticals, INC. | $21.03 | 2022 | |
| Medexus Pharma, INC. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.